Mainstay Medical announced that it received FDA premarket approval for its ReActiv8 implantable neurostimulation system for chronic low back pain. ReActiv8 treats intractable chronic low back pain associated with multifidus muscle dysfunction, as evidenced by imaging or physiological testing in adults who have failed therapy and are not candidates for spine surgery, according to a […]
Mainstay Medical
Smith & Nephew CEO Bohuon to retire | Personnel Moves – Oct. 10, 2017
Smith & Nephew (NYSE:SNN) said today that its current CEO Olivier Bohuon has announced his intention to retire by the end of 2018 and that the company has begun a search for a new chief exec. Bohuon joined the company in 2011, and has overseen a significant rise in share value with the company since taking the […]
Mainstay Medical taps ex-NuVasive COO Hannon for CEO | Personnel Moves, Sept. 7, 2017
Mainstay Medical (EPA:MSTY) said this week that it tapped former NuVasive Inc. (NSDQ:NUVA) president & COO Jason Hannon to succeed Peter Crosby as CEO, effective Oct. 9. Crosby, recruited in 2009 to lead the company and its development of the Reactiv8 neurostimulation device for treating chronic pain, is slated to act as a consultant for Mainstay through […]
Mainstay Medical pulls in $34m for Reactiv8 neurostim device for chronic pain
Mainstay Medical (EPA:MSTY) said last week that it raised a $34 million (€30 million) equity round for its Reactiv8 neurostimulation device, including a $17 million (€15 million) contribution from family investment fund KCK. Proceeds from the 2.3-million-share flotation, priced at $14.70 apiece (€13.00), are slated for European commercialization of the Reactiv8 device (the system won CE Mark approval in […]
Mainstay Medical wins CE Mark for ReActiv8 neurostim
Mainstay Medical (EPA:MSTY) said today it won CE Mark approval for its ReActiv8 implantable neurostimulation system designed to treat chronic lower back pain. The device was approved based off data from the company’s ReActiv8-A trial, which reported statistically significant, lasting improvements in pain, disability and quality of life in patients with chronic low back pain and […]
Mainstay: ReActiv8 data may be enough for CE Mark, announces earnings
Mainstay Medical (EPA:MSTY) said that data from a trial of its ReActiv8 neurostim may be enough to win it CE Mark approval in the European Union and released its 6-month earnings today. The company’s multi-center, prospective ReActiv8-A clinical trial examined patients with chronic lower back pain treated with the company’s implantable ReActiv8 neurostimulation device. Of the […]
Mainstay Medical raises $15m
Mainstay Medical (EPA:MSTY) said yesterday it raised $15 million in a debt financing round to help fund its ReActiv8 implantable device for individuals with chronic low back pain. The debt facility came from IPF Partners, according to Dublin, Ireland-based Mainstay. “We are pleased to have secured this $15 million debt facility. These funds strengthen our financial […]
Report: Mainstay Medical’s IPO raises $25M
Mainstay Medical‘s (MSTY.PA) European initial public offering reeled in about $25 million (€18 million) and made the spinal implant maker the 1st medtech company to float an IPO in Paris and the 1st company to attempt a dual flotation in Paris and Dublin, the Irish Times reports.
Mainstay Medical readies European IPO
Mainstay Medical is preparing an initial public offering on the EuroNext stock exchange that could be worth up to $42 million, according to a regulatory filing.
Mainstay, which last month launched a new clinical trial of its ReActiv8 implantable neurostimulator for chronic lower back pain, said it plans to offer some 1.1 million shares at €20-€27 per share, or about $27.77 to $37.50 per share.
Mainstay Medical launches human trial of pain-relief stimulation implant
Dublin-based Mainstay Medical touted the launch of a new clinical trial evaluating its ReActiv8 implantable neurostimulator at 3 clinical sites in Australia.
Sony picks up 11% Olympus stake for $640M | Wall Street Beat
Sony Corp. (TYO:6758) plans to become the largest shareholder in Olympus (TYO:7733) with a $642 million investment that will give it an 11% stake in Olympus.
